Treatment of Relapsed and Refractory AML with Mitoxantrone and Etoposide: A Study of the Eastern Cooperative Oncology Group

  • J. M. Rowe
  • J. W. Andersen
  • J. J. Mazza
  • J. D. Hines
  • J. M. Bennett
  • P. A. Cassileth
  • E. Mansour
  • M. M. Oken
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 36)


The treatment of relapsed and refractory AML remains unsatisfactory. It has generally been assumed that, for such patients, the possibility of long-term disease-free survival when treated with chemotherapy is almost negligible. The main focus of therapy rests with attempts to optimize the likelihood of achieving a complete remission (CR) and then either prolong the CR [l] or attempt to induce a long-term disease-free survival using some form of intensive chemotherapy or bone marrow transplantation.


Acute Myeloid Leukemia Acute Leukemia Complete Remission Rate Nonhematological Toxicity Refractory Acute Myeloid Leukemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Cassileth PA, Harrington DP, Hines JD et al. (1988) Maintenance chemotherapy prolongs initial complete remission duration in adult acute nonlymphocytic leukemia. J Clin Oncol 6: 583–589PubMedGoogle Scholar
  2. 2.
    Double JC, Brown JR (1976) Evaluation of the binding of some substituted anthraquinones and naphthacenequinones to DNA. J Pharm Pharmacol 28: 166–169PubMedCrossRefGoogle Scholar
  3. 3.
    ZE-Cheng RKY, Cheng CC (1974) Antineoplastic agents. Structure and activity relationship study of bis (substituted aminoalkylamino (anthraQuinones). J Med Chern 21: 291–294CrossRefGoogle Scholar
  4. 4.
    Arlin Z, Silver R, Cassileth PA et al. (1984) Phase I/II trial of mitoxantrone in acute leukemia. Cancer Treat Rep 69: 61–64Google Scholar
  5. 5.
    Moore JO, Olsen GA (1984) Mitoxantrone in the treatment of relapsed and refractory acute leukemia. Semin Oncol 11(3): 41–46PubMedGoogle Scholar
  6. 6.
    Paciucci PA, Cuttner J, Holland JS (1984) Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia. Semin Oncol 11 (3): 36–40PubMedGoogle Scholar
  7. 7.
    Van Echo DA, Wiernik PH, Aisner J (1980) High-dose VP-16-213 for the treatment of patients with previously treated acute leukemia. Can Clin Trials 3(4): 325–328Google Scholar
  8. 8.
    Bennett JM, Lymann GM, Cassileth PA et al. (1984) A phase II trial of VP-16 in adults with refractory acute myeloid leukemia. An ECOG study. Am J Clin Oncol (CCT) 7: 471–473CrossRefGoogle Scholar
  9. 9.
    Rowe JM, Mazzan JJ, Hines JD et al. (1990) Mitoxantrone and etoposide in patients with relapsed and refractory acute non-lymphocytic leukemia. Acute Leukemias II ed. Buchner et al. In Hematology and Blood Transfusion 33: 326–329, Springer-Verlag, Berlin HeidelbergGoogle Scholar
  10. 10.
    Rowe JM, Oken MM, Cassileth PA et al. (1992) Clinical trials in adults with relapsed and refractory acute myelogenous leukemia. The ECOG and University of Rochester experience. Acute Leukemias III ed. Hiddemann et al. In Hematology and Blood Transfusion 34: 392–395, Springer-Verlag, Berlin, HeidelbergGoogle Scholar
  11. 11.
    Cassileth PA, Begg CB, Bennett JM et al. (1984) A randomized study of efficacy of consolidation therapy in adult acute non-lymphocytic leukemia. Blood 63(4): 843–847PubMedGoogle Scholar
  12. 12.
    Oken MM, Creech R, Tormey D et al. (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649–653PubMedCrossRefGoogle Scholar
  13. 13.
    Ho Ad, Lipp T, Ehninger G et al. (1988) Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia – an active and well tolerated regimen. J Clin Oncol 6(2): 213–217PubMedGoogle Scholar
  14. 14.
    Lazzarino M, Morra E, Alessandrino EP (1988) Mitoxantrone-etoposide combination chemotherapy for relapsed and refractory acute myeloid leukemia (AML) in adults. Blood 72(5): 210a (abstr)Google Scholar
  15. 15.
    Hiddemann W, Buchner T (1990) Treatment strategies for relapsed acute myeloid leukemia - a proposal based on the definition of refractoriness against conventional chemotherapy (1990) in Acute Myelogenous Leukemia: Progress and Controversies ed. Gale RP, Wiley-Liss, Inc. 363–373Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • J. M. Rowe
    • 1
  • J. W. Andersen
    • 2
  • J. J. Mazza
    • 3
  • J. D. Hines
    • 4
  • J. M. Bennett
    • 5
  • P. A. Cassileth
    • 6
  • E. Mansour
    • 7
  • M. M. Oken
    • 8
  1. 1.Hematology UnitUniversity of Rochester Medical CenterRochesterUSA
  2. 2.Dana Farber Cancer InstituteBostonUSA
  3. 3.Marshfield ClinicMarshfieldUSA
  4. 4.Cleveland Metropolitan HospitalClevelandUSA
  5. 5.Cancer CenterUniversity of Rochester Medical CenterRochesterUSA
  6. 6.Sylvester Comprehensive Cancer CenterUniversity of MiamiMiamiUSA
  7. 7.Case Western Reserve UniversityClevelandUSA
  8. 8.Virginia Piper Cancer InstituteMinneapolisUSA

Personalised recommendations